Antimicrobial compositions of wide spectrum of action based on taurolidine and protamine combininations and medical devices containing such compositions

FIELD: pharmacology.

SUBSTANCE: group of inventions designed for antimicrobial treatment of implantable medical devices. The antimicrobial composition for antimicrobial coating application to medical devices contains about 50 to 99 wt % of taurolidine and about 1 to 50 wt % of protamine. For medical device coating, a medical device with at least one surface is provided and at least a portion of the said antimicrobial coating is applied to the surface. Polymeric resin which comprises the said composition is also provided for the manufacture of medical devices.

EFFECT: antimicrobial composition effective against a wide range of microbes.

80 cl, 2 dwg, 3 tbl, 4 ex



Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention deals with application of composition, which includes hydrolysate of pea protein and/or peptide for obtaining composition for treatment and/or prevention of infection Helicobacter pylori (versions), as well as such compositions (versions). Characterised compositions include lipid, protein and carbohydrate component, in which protein component includes protein source, which consists of pea protein hydrolysate, obtained by hydrolysis with protease, different from chymotrypsin, or from peptides, selected from group, which consists of Xaan-Asp-Phe-Leu-Glu-Asp-Ala-Phe-Asn-Val-Asn-Arg-Xaam and Xaan-Glu-Leu-Ala-Phe-Pro-Gly-Ser-Ala-Gln-Glu-Val-Asp-Arg-Xaam, where each Xaa independently can be any amino acid, and n and m are integer numbers, independently varying from 0-10, where peptide is contained in pea protein hydrolysate, or from both.

EFFECT: claimed inventions make it possible to treat or prevent diseases, caused by Helicobacter pylori infection, and/or diseases, associated with infection Helicobacter pylori in mammals.

17 cl, 2 tbl, 1 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises subcutaneous administration of antibiotic preparation enroxyl 5% at a dose of 0.1 ml/kg daily one time a day for 7 days and intramuscular administration of homeopathic preparation ovarinin at a dose of 1 ml/kg one time for 4 days, 4-fold.

EFFECT: use of the invention enables to increase the efficiency of treatment, to reduce treatment time and to restore reproductive function of dogs.

2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine and describes pharmaceutical composition, including therapeutically effective quantity of compound, which has the following structure: , where compound in pharmaceutical composition is present in quantity, efficient for treatment or prevention of antibacterial infection in mammalian subject. Methods of obtaining and application of said dosed forms or pharmaceutical compositions are also claimed.

EFFECT: obtaining composition for treatment or prevention of antibacterial infection in mammalian subject.

15 cl, 8 tbl, 5 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: group of inventions refers to veterinary science and is applicable for treating bovine mastitis. What is declared is a nosode for producing a preparation for treating bovine mastitis. That involves taking mastitis milk 1 ml with clinical signs of purulent-catarrhal mastitis, filling it 70° alcohol 9 ml to produce a homogenous solution; the produced solution is diluted to "Д6" with 70° alcohol. What is also declared is a preparation for treating bovine mastitis containing an aqueous-alcoholic solution of components. The components are Belladonna, Sulphur, Apis mellifica, Conium, Phytolacca, Silicea and above nosode in the following proportions, wt %: Belladonna - 5, Sulphur - 20, Apis mellifica - 20, Conium - 10, Phytolacca - 10, Silicea - 5, nosode - 15, aqueous-alcoholic solution up to 100%. What is also declared is a method of treating bovine mastitis involving the intracisternal administration of the preparation. The preparation is administered in a dose of 5-10 ml per 1 animal once a day.

EFFECT: declared group of inventions is highly effective in treating bovine mastitis.

3 cl, 5 tbl, 1 ex

Antimicrobial agent // 2556509

FIELD: medicine.

SUBSTANCE: compound 2-(1'-hydroxy-4'-isopropenyl-1'-methylcyclohexyl-2'-thio)-methylethanoate having structural formula I: is applicable as an antimicrobial agent.

EFFECT: using the compound of formula I possessing antimicrobial activity provides treating infectious processes caused by susceptible organisms.

5 tbl

FIELD: medicine.

SUBSTANCE: claimed group of inventions relates to field of veterinary. Claimed are: vaccine, aimed against actinobacillous pleuropneumonia, including lipopolysaccharide in complex with one or more repeats of ApxI, ApxII and ApxIII toxins, separated from bacterial culture and polymyxin to reduce symptoms of endotoxic shock, caused by lipopolysaccharide, method of obtaining such vaccine, application of polymyxin to reduce endotoxic shock symptoms when vaccine is introduced, in which polymixyn is added into vaccine in dose from 2.6 to 60 mcg/ml.

EFFECT: claimed group of inventions provides effective means and methods to reduce endotoxic shock symptoms, caused by lipopolysaccharide, when vaccine against actinobacillous pleuropneumonia is introduced to animal.

14 cl, 4 tbl, 4 ex

FIELD: veterinary medicine.

SUBSTANCE: complex antibacterial agent for animals, containing a compound from the group of fluoroquinolones and auxiliary substances, characterised in that it additionally comprises a compound from the group of pleuromutilins in an effective amount.

EFFECT: invention is effective against vegetative and spore forms of bacteria, it is harmless, has no allergenic properties, has a stimulating effect on the indices of humoral immune response, and is stable during storage.

6 cl, 9 ex

FIELD: veterinary medicine.

SUBSTANCE: agent comprises enrofloxacin and excipients. The agent additionally comprises humates of peat or sapropel, with the following ratio of the components, wt %: enrofloxacin substance - 0.5; alkaline solution of humates (pH=12-13) - 80; succinic acid - to pH 10-11; propylene glycol - the rest. The agent is administered with the liquid feed once a day for three to five days at a dose of from 0.5 to 1.0 ml per 1 kg of body weight.

EFFECT: manifestation of pronounced therapeutic effect.

5 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to method of obtaining 7-hydroxyroyleanon, possessing antimicrobial action. said method includes extraction of crushed roots of salvia officinalis with 96% ethyl alcohol with further extract evaporation, processing with water, alcohol distillation and processing with hydrophobic solvent or extraction of said raw material with chloroform with further extract processing with water and evaporation; after which target product is extracted from organic phase by transfer into water-soluble phenolates, with processing with sodium hydroxide water solution; alkali solution is washed with chloroform; acidified with hydrochloric or sulphuric acid; obtained sediment is filtered; dried and crushed.

EFFECT: invention is characterised by improved process manufacturability and provides obtaining individual substance with higher antimicrobial activity than previously extracted royleanon derivatives from salvia officinalis.

2 tbl, 6 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to a strain of the pathogen of pseudomonosis of pigs of the collection of Federal state budgetary institution "VGNKI", deposited under the name "Pseudomonas aeruginosa No.9" and the registration number "No.9-DEP", intended for production of a vaccine against pseudomonosis of pigs.

EFFECT: invention provides high immunogenic activity and the ability of production of the vaccine against pseudomonosis of pigs.

4 ex, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology, more specifically to AXL signalling pathway inhibitors, and can be used in medicine. What is produced is a soluble AXL polypeptide version free from AXL transmembrane domain, which contains at least one amino acid modification in position No. n, wherein n is specified in 32, 72, 87, 92 or 127 or a combination thereof, wherein n+7 is described by numbering SEQ ID NO: 1 that are wild-type AXL sequences, wherein the above modification increases a AXL polypeptide binding affinity to protein 6 specifically inhibiting the growth (GAS6), which is twice as strong as the wild-type AXL polypeptide affinity. The polypeptide can be fused with Fc fragment and used in a method of treating, reducing or preventing tumour dissemination and invasion in a mammalian patient.

EFFECT: invention enables inhibiting the AXL/GAS6 signalling pathways effectively.

8 cl, 15 dwg, 6 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology, specifically to novel hetero-multimeric proteins obtained from modified ubiquitin, and can be used in medicine to treat or diagnose diseases associated with hyperprodution of the extradomain B of fibronectin (ED-B). The protein includes two monomeric ubiquitin links which are differently modified through substitutions of at least 6 amino acids in positions 4, 6, 8, 62, 63, 64, 65 and 66 of SEQ ID NO: 1. In the first monomer link the substitutions include: F4W, K6(H, W or F), Q62N, E64(K, R or H), S65(L, F or W), T66(S or P), and in the second monomer link: K6(T, N, S or Q), L8(Q, T, N or S), Q62(W or F), K63(S, T, N or Q), E64(N, S, T or Q), S65(F or W), T66(E or D).

EFFECT: invention enables to obtain a modified heterodimeric ubiquitin protein, capable of binding with ED-B with high affinity.

28 cl, 18 dwg, 3 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: what is presented is using H1.3 recombinant histone protein as an eukaryotic cell adenoviral transduction inhibitor. The invention can be used to producing drug preparations for the diseases related to adenoviral infection.

EFFECT: higher clinical effectiveness.

2 dwg, 1 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: group of inventions refers to biotechnology. What is presented is a precursor protein for the recombinant preparation of peptides having a length of a sequence of 5 to 70 amino acid residues. The above protein contains a splittable recurrent sequence of target peptide elements (Pep) and auxiliary peptide elements (Aux) of general formula: (Pep-Aux)x or (Aux-Pep)x, wherein x>1. The elements Aux contain a self-assembled peptide element (SA). The elements Pep contain an amino acid sequence having a length of the sequence of 5 to 70 amino acid residues; ends of the elements comprise splittable sequences, which enable releasing the elements Pep from the precursor protein by specific splitting. There are also presented a nucleic acid molecule with a nucleic acid sequence coding the above precursor protein, an expression cartridge and a recombinant expression vector containing the sequence of the above nucleic acid. There are also presented a variant of the precursor protein, a method for producing the target peptide Pep, as well as using an amphiphilic peptide for the recombinant production of the antimicrobial target peptide.

EFFECT: group of inventions provides the higher yield of the target peptides.

24 cl, 11 dwg, 1 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, pharmaceutics and biochemistry, and concerns a metastatic melanoma grade marker containing the amino acid sequence SEQ ID NO:1. There are also declared a recovered antibody and a monoclonal antibody, which recognise human TM9SF4 protein by binding to a peptide fragment of SEQ ID NO:1, as well as a kit for determining a tumour grade comprising the above antibody, using SEQ ID NO:1 for determining the metastatic pattern of melanoma.

EFFECT: group of inventions provides the faster detection of melanoma metastasis.

10 cl, 8 ex, 2 tbl, 10 dwg

FIELD: medicine.

SUBSTANCE: invention refers to microbiology and molecular genetics, and concerns recombinant polypeptide StV, recombinant DNA stV coding the above recombinant polypeptide StV, recombinant plasmid DNA PQE-stV representing plasmid DNA PQE-30 carrying the above recombinant DNA stV, and the producing strain Escherichia coli M15-StV producing recombinant polypeptide StV.

EFFECT: presented inventions can be used in medical industry in producing Streptococcus agalactiae, eg Streptococci B vaccines.

4 cl, 6 dwg, 2 tbl, 5 ex

Anti-tumour agent // 2541130

FIELD: medicine.

SUBSTANCE: invention represents an anti-tumour agent containing glucocorticoid hormone in an amount of 0.3 mcg%-40 mcg%, very low-density lipoproteins in an amount to provide the apolipoprotein E content in a formulation of not less than 1 mg%, and additionally a physiologically acceptable solvent, which can be used to inhibit the tumour growth by initiating the tumour cell apoptosis.

EFFECT: higher effectiveness of the antitumour agent and extended indications for use.

2 cl, 3 ex, 6 tbl, 5 dwg

FIELD: biotechnologies.

SUBSTANCE: peptide is characterised with sequence Lys-Leu-Lys-Gln-Lys-Leu-Ala-Glu-Leu-Leu-Glu-Asn-Leu-Leu-Glu-Arg-Phe-Leu-Asp-Leu-Val-Inp (SEQ ID NO: 16). The invention also relates to peptide/lipid complex based on the above peptide, in which phospholipid represents one or more of sphingomyelin, DPPC and DPPG, a pharmaceutical composition that contains it, and treatment methods of dyslipidemia, cardiovascular disease, endothelial malfunction, macrovascular illnesses and microvascular illnesses using it.

EFFECT: invention allows obtaining ApoA-I mimetic that is more stable in comparison to ApoA-I and that is easy to obtain.

14 cl, 21 dwg, 14 tbl, 24 ex

FIELD: medicine.

SUBSTANCE: invention relates to protein-containing nutritional compositions. A method of prevention or reduction of coagulation in the upper part of the gastrointestinal tract of a subject of coagulating protein, present in a nutritional composition, includes additional introduction of an anticoagulation protein into the said nutritional composition. As the anticoagulation protein used is pea protein or soya protein. Also claimed is a method of prevention or treatment of intestinal discomfort, aspiration pneumonia, high gastrointestinal tract residual volume (GRV), vomiting, nausea, bloating and delayed emptying of the gastrointestinal tract or a support of the gastrointestinal tract comfort, reduction of spasms and/or colics in the gastrointestinal tract in a subject, which requires it, which includes introduction of the said nutritional composition to the said subject.

EFFECT: invention makes it possible to control coagulation of proteins in the process of their digestion and prevent complications in the upper part of the gastrointestinal tract.

23 cl, 1 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of biochemistry, in particular to a polypeptide, which is capable, when fused with a biologically active polypeptide, of increasing its half-life time in serum, as well as to its application for increasing the half-life time in the circulation of erythropoietin, the stimulation factor of granulocyte colony, p40 and a receptor of the tumour necrosis factor. Disclosed are a molecule of nucleic acid, coding the said polypeptide, containing it expression vector, as well as a method of obtaining the said polypeptide by an introduction of a nucleic acid molecule, which codes it, into a mammalian host cell, its growth, as well as collection of the expressed polypeptide.

EFFECT: invention makes it possible to increase the time of half-life of the biologically active polypeptide in serum in an efficient way.

15 cl, 9 dwg, 1 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention concerns rehabilitation of elderly patients with ischemic heart disease (IHD) accompanied by chronic heart insufficiency (CHI) following myocardial in myocardial infarction (MI). That is ensured by administering Omacor, a preparation of omega-3-polyunsaturated fatty acids in the remote period, 6 or more months after the suffered MI with underlying a standard drug therapy 60 minutes before the graduated walking.

EFFECT: this complex of the drug preparations combined with the graduated physical exercises provides higher tolerance to physical exercises, improving the cardiovascular function and normalising the lipid exchange that in turn leads to reducing a number of unfavourable cardiovascular episodes and delaying CHI.

2 ex, 5 tbl